2m 2m 2m 2m 2m 2m 2m
Sarepta Therap (SRPT)
NASDAQ
$17.28+$0.02 (+0.12%)
Price as of Jun 23, 2026 7:50 PM EDT- $1.9BMarket Cap
- -9.06%1-Year Change
- BiotechnologyIndustry
Sarepta Therap (SRPT)
$17.28+$0.02 (+0.12%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 2.2B +15.58% | 1.9B +52.97% | 1.2B +33.26% | 933.0M +32.93% | |
Cost of Revenue | 23.0M +203.38% | -22.2M N/A | N/A N/A | N/A N/A | |
Gross Profit | 2.2B +13.04% | 1.9B +54.76% | 1.2B +33.26% | 933.0M +32.93% | |
Sales and Marketing Expense | 491.7M -11.86% | 557.9M +15.77% | 481.9M +6.75% | 451.4M +59.70% | |
Research and Development Expense | -1.5B +89.19% | -804.5M -8.30% | -877.4M +0.03% | -877.1M +13.73% | |
Depreciation and Amortization Expense | 44.5M +18.02% | 37.7M -15.03% | 44.4M +6.05% | 41.9M +10.12% | |
Total Operating Expenses | 2.9B +72.10% | 1.7B +11.43% | 1.5B +2.85% | 1.5B +26.48% | |
Operating Profit | -699.8M -397.48% | 235.2M +187.83% | -267.8M -50.05% | -536.2M +16.64% | |
Interest Income | 30.8M +0.42% | 30.6M -15.51% | 36.3M +119.90% | 16.5M +4,557.63% | |
Interest Expense | -38.1M +107.38% | -18.4M -16.44% | -22.0M -58.67% | -53.2M -16.18% | |
Interest Income and Expense and Net | -7.4M -160.25% | 12.2M -14.06% | 14.2M +138.76% | -36.8M -41.81% | |
Total Nonoperating Income and Expense | -2.4M -105.72% | 42.7M +116.92% | -252.3M +64.07% | -153.8M -477.22% | |
Income before Taxes | -713.4M -403.27% | 235.2M +145.23% | -520.1M -24.62% | -690.0M +64.69% | |
Income Taxes | 11.2M -56.20% | 25.5M +60.81% | 15.9M +17.40% | 13.5M +8,150.60% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -713.4M -403.27% | 235.2M +143.89% | -536.0M -23.81% | -703.5M +67.99% | |
Net Income from Continuing Operations Applicable to Common | -713.4M -382.83% | 252.2M +148.50% | -520.1M -24.62% | -690.0M +64.69% | |
Basic EPS and Net Income | -7.13 -388.66% | 2.47 +142.59% | -5.80 -27.77% | -8.03 +55.92% | |
Diluted EPS and Net Income | -7.13 -404.70% | 2.34 +140.34% | -5.80 -27.77% | -8.03 +55.92% | |
Basic Weighted Average Shares | 100.1M +5.31% | 95.1M +2.90% | 92.4M +5.53% | 87.6M +7.75% | |
Diluted Weighted Average Shares | 100.1M -7.19% | 107.9M +16.75% | 92.4M +5.53% | 87.6M +7.75% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 801.3M -27.35% | 1.1B +157.45% | 428.4M -55.68% | 966.8M -54.31% | |
Short-Term Investments | 138.4M -45.04% | 251.8M -79.82% | 1.2B +22.02% | 1.0B N/A | |
Cash and Cash Equivalents and Short-Term Investments | 939.6M -30.64% | 1.4B -19.18% | 1.7B -15.74% | 2.0B -5.98% | |
Total Current Assets | 2.5B -17.42% | 3.1B +19.16% | 2.6B +0.84% | 2.6B -1.78% | |
Accumulated Depreciation | 280.5M +20.01% | 233.7M +22.38% | 191.0M +28.27% | 148.9M +32.18% | |
Property and Plant and Equipment and Net | 345.1M +1.41% | 340.3M +49.83% | 227.2M +26.17% | 180.0M -5.82% | |
Total Long-Term Assets | 155.6M +94.65% | 79.9M -41.57% | 136.8M -56.98% | 317.9M +8.53% | |
Total Assets | 3.3B -15.48% | 4.0B +21.40% | 3.3B +4.35% | 3.1B -0.62% | |
Income Taxes Payable | 4.8M -72.66% | 17.4M +26.33% | 13.8M +9.94% | 12.5M N/A | |
Total Short-Term Debt | N/A N/A | 0 -100.00% | 105.5M N/A | N/A N/A | |
Total Current Liabilities | 1.1B +49.69% | 731.7M +11.94% | 653.7M +5.50% | 619.6M +36.86% | |
Total Long-Term Debt | 829.0M -27.10% | 1.1B +0.41% | 1.1B -26.66% | 1.5B +40.79% | |
Total Long-Term Liabilities | 1.5M -12.63% | 1.8M -41.67% | 3.0M +7,042.86% | 42,000 -99.62% | |
Total Liabilities | 2.2B -9.29% | 2.4B +1.26% | 2.4B -12.33% | 2.7B +23.58% | |
Retained Earnings | -4.9B +15.82% | -4.2B -5.29% | -4.4B +13.71% | -3.9B +21.94% | |
Total Stockholders Equity | 1.1B -25.34% | 1.5B +77.78% | 859.3M +123.23% | 384.9M -58.52% | |
Total Shares Outstanding | 105.0M +8.32% | 96.9M +3.38% | 93.7M +6.57% | 88.0M +0.94% | |
Cash Flow | |||||
Cash from Operating Activities | -205.5M -0.15% | -205.8M -58.92% | -501.0M +53.99% | -325.3M -26.59% | |
Capital Expenditures | 102.0M -25.54% | 137.0M +79.95% | 76.1M +146.91% | 30.8M -19.92% | |
Cash from Investing Activities | 69.6M -90.78% | 755.6M +555.70% | -165.8M -84.16% | -1.0B -311.32% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -168.3M -234.88% | 124.8M -0.16% | 125.0M -46.24% | 232.5M -58.60% | |
Financials Ratio | |||||
Gross Margin | 98.95% -2.19% | 101.17% N/A | N/A N/A | N/A N/A | |
Operating Margin | -31.83% -357.39% | 12.37% +157.42% | -21.54% -62.52% | -57.47% -12.25% | |
Return on Assets | -19.51% -399.74% | 6.51% +138.82% | -16.77% -25.20% | -22.42% +64.14% | |
Return on Equity | -53.47% -371.30% | 19.71% +122.88% | -86.15% -19.61% | -107.16% +116.20% | |
Revenue Growth | 15.58% -70.60% | 52.97% +59.27% | 33.26% +1.01% | 32.93% +9.93% | |
Current Ratio | 2.32 -44.84% | 4.20 +6.45% | 3.95 -4.41% | 4.13 -28.23% | |
Cash Ratio | 0.73 -51.47% | 1.51 +130.01% | 0.66 -58.00% | 1.56 -66.61% | |
Debt-to-Equity Ratio | N/A N/A | 0.74 -48.33% | 1.44 N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | 0.29 -24.34% | 0.38 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow